A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Summary

This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no longer clinically benefiting from therapy due to disease progression, adverse events, or another discontinuation criterion. Safety, tolerability and efficacy of BBI503 will be assessed for the duration of study treatment.

Timeline

Start

2017-03-13

Primary completion

2017-07-25

Completion

2017-07-25

Drugs

Indications